Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Waldenstrom Macroglobulinemia: Non-BTK Novel Strategies

July 26th 2019

BTK Inhibition's Role in Waldenstrom Macroglobulinemia

July 26th 2019

Waldenstrom Macroglobulinemia: Indications for Treatment

July 26th 2019

Practical Advice on the Future Management of MCL

July 26th 2019

R/R MCL: Synchronizing Older and Newer Therapeutic Strategies

July 26th 2019

Selection of a BTK Inhibitor in Relapsed/Refractory MCL

July 26th 2019

Mantle Cell Lymphoma: An Overview on Frontline Therapy

July 26th 2019

CLL: Practical Advice on Selecting and Managing Therapy

July 26th 2019

Acalabrutinib's Role in Treating Chronic Lymphocytic Leukemia

July 26th 2019

Venetoclax + Obinutuzumab: Impact on CLL Management

July 26th 2019

Frontline Therapy in CLL: Combination Strategies and MRD

July 26th 2019

Stratifying Patients With CLL to Frontline Therapy

July 26th 2019

Ibrutinib's Role as Frontline Therapy in CLL

July 26th 2019

Dr. Hou on Polatuzumab Vedotin in DLBCL

July 25th 2019

Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the use of polatuzumab vedotin (Polivy) in diffuse large B-cell lymphoma (DLBCL).

Targeted Agents Transforming AML Paradigm

July 24th 2019

Elias Jabbour, MD, highlights the evolving armamentarium and next steps in the treatment paradigm for acute myeloid leukemia.

FDA Approves Rituximab Biosimilar for CD20+ B-Cell Non-Hodgkin Lymphoma and CLL

July 23rd 2019

The FDA has approved PF-05280586, a biosimilar for rituximab, for the treatment of adult patients with CD20-positive B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy, or for patients with CD20-positive chronic lymphocytic leukemia in combination with chemotherapy.

The Future Treatment Landscape of AML

July 22nd 2019

Targeting IDH1/2 in AML

July 22nd 2019

Relapsed vs. Refractory Data for FLT3 Inhibitors in AML

July 22nd 2019

Data Supporting Quizartinib in FLT3+ R/R AML

July 22nd 2019